China’s Shanghai Pharma is planning to open an R&D unit in San Diego as part of an international expansion drive that could also include acquisitions in…
Biogen is paying $10 million upfront and committing to up to $207 million more in milestones to buy the IND-ready oral SINE compound.
Disarm has poached Big Pharma executive Thomas Engber, Ph.D., as its new SVP and head of neuropharmacology and translational sciences.
Tmunity will develop its T-cell therapies first using UPenn's facilities and eventually expanding to its own sites.
Celgene agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal instantly making it a big cheese in therapeutics.
Van Herk Investments thinks Novo’s recent offer was too low, but it will encourage Ablynx to enter talks if a sufficiently sweetened bid is received.
Gilead and its $12 billion biotech buy Kite Pharma have teamed up with Pfizer to work on a Yescarta-utomilumab combo test in certain blood cancers.
Celgene is lining up another deal for CAR-T biotech Juno Therapeutics, according to several media reports.
We catch up with Doug Ingram, chief at rare disease biotech Sarepta, and discuss how he aims to remove the term “controversial” in front of the company’s name.
Roche joins Merck KGaA as pharma parter for Forty Seven's CD47-targeting antibody, which blocks a "don't eat me" signal sent out by…